TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31615803

Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 30046837

Group type: EXPERIMENTAL
Intervention: MDCO-216 (20 mg/kg weekly for 5 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 27377956

Group type: EXPERIMENTAL
Intervention: Seductive details
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 25256180

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Primary composite end point (any stroke, myocardial infarction, or death within 30 days or ipsilateral stroke in follow-up)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Stroke and death
Number of subjects: 477
Study: 22123525

Group type: EXPERIMENTAL
Intervention: Dexpanthenol cream once daily (B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 min wIRA irradiation at 30 cm distance (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: wIRA irradiation for 30 min once daily together with dexpanthenol cream once daily (D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments (B-D)
Number of subjects: 0
Study: 19925461

Group type: EXPERIMENTAL
Intervention: Bispectral index (BIS) monitoring
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 26
Study: 18562739

Group type: EXPERIMENTAL
Intervention: iopamidol 370
Number of subjects: 263

Group type: COMPARATOR
Intervention: iodixanol 320
Number of subjects: 263
Study: 15855263

Group type: EXPERIMENTAL
Intervention: L-T(4) replacement
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: sHT patients
Number of subjects: 23
Study: 12421103

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 to 600mg followed by oral misoprostol 0.4 to 0.6mg or vaginal gemeprost 1.0mg/misoprostol 0.8mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 0
Study: 9474632

Group type: EXPERIMENTAL
Intervention: Medial trivector approach
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard medial parapatellar arthrotomy
Number of subjects: 10
Study: 7618966

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0
Study: 2122251

Group type: EXPERIMENTAL
Intervention: Heparin (5000-unit bolus followed by continuous intravenous heparin)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Aspirin (80 mg daily oral)
Number of subjects: 205
Study: 386913

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31957143

Group type: EXPERIMENTAL
Intervention: Adult coloring pack
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo pack
Number of subjects: 53
Study: 30857515

Group type: EXPERIMENTAL
Intervention: Î±-stat approach to ABG analysis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: pH-stat approach to ABG analysis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Î±-stat approach for randomised controlled trial
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: pH-stat approach for randomised controlled trial
Number of subjects: 70
Study: 30021543

Group type: EXPERIMENTAL
Intervention: Screening plus eave tubes (SET) + Long-Lasting Insecticidal Nets (LLINs)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Long-Lasting Insecticidal Nets (LLINs) only
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Screening plus eave tubes (SET) + LLINs
Number of subjects: 200
Study: 26967821

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 103
Study: 25347623

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 93
Study: 22157279

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg BID
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Naproxen 300 mg BID
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride 750 mg BID
Number of subjects: 183
Study: 20670323

Group type: EXPERIMENTAL
Intervention: Mnemonic 44-55-66-PM
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (classic description of OAR)
Number of subjects: 206
Study: 17569792

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AirHeel brace
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of eccentric training and AirHeel brace
Number of subjects: 100
Study: 15788347

Group type: EXPERIMENTAL
Intervention: Exercise therapy aimed at restoring dynamic stabilizing mechanisms and muscle co‐ordination at the shoulder
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Combination of physical modalities and range of motion exercises
Number of subjects: 138
Study: 11889011

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10077394

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 286

Group type: COMPARATOR
Intervention: N-terminal proANP levels before PTCA
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Changes in N-terminal proANP from post-PTCA to final follow-up
Number of subjects: 286
Study: 7627696

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 303

Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 303
Study: 1790251

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin, 0.2 mg/kg, i.v. 24 h after birth
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 36
Study: 6759136

Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carprofen (100 mg in the morning plus 200 mg in the evening)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carprofen (100 mg 3 times daily)
Number of subjects: 20
Study: 31284844

Group type: EXPERIMENTAL
Intervention: Circuit exercise training (25-75 minutes, three times per week for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (usual daily lifestyle)
Number of subjects: 26
Study: 28891835

Group type: EXPERIMENTAL
Intervention: Dextromethorphan premedication
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25825410

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 12956
Study: 24642379

Group type: EXPERIMENTAL
Intervention: Baseline ALT
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Baseline AST
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Baseline Albumin
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Baseline Total Protein
Number of subjects: 234
Study: 22786569

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ (50 mg losartan + 12.5 mg hydrochlorothiazide per day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Maximal-dose ARB
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ
Number of subjects: 193
Study: 20012639

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 17728684

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16128944

Group type: COMPARATOR
Intervention: Symptomatic management (control arm)
Number of subjects: 106
Study: 12399289

Group type: EXPERIMENTAL
Intervention: Purified isoflavone preparation (formulation A) with a genistein dose of 2, 4, 8, or 16 mg/kg body wt
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Purified isoflavone preparation (formulation A)
Number of subjects: 24
Study: 10191165

Group type: EXPERIMENTAL
Intervention: Multislice echo-planar imaging (EPI) with repetition times (TR) of 6.0, 3.0, and 1.5 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slice thickness ranging from 1 to 8 mm
Number of subjects: 0
Study: 7477218

Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine every 12 hours
Number of subjects: 366

Group type: COMPARATOR
Intervention: 200 mg of zidovudine every 8 hours
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 150 mg of lamivudine every 12 hours plus zidovudine
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine every 12 hours plus zidovudine
Number of subjects: 366
Study: 2155751

Group type: EXPERIMENTAL
Intervention: 400 units of intranasal calcitonin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcitonin (1, 10, 100 units)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7250475

Group type: EXPERIMENTAL
Intervention: Aromatic retinoid Ro 10-9359 (AR) combined with PUVA therapy (schedule C)
Number of subjects: 126

Group type: COMPARATOR
Intervention: PUVA therapy alone
Number of subjects: 126
Study: 30488331

Group type: EXPERIMENTAL
Intervention: Abstinence from social media for up to one week (less if they 'broke' and resumed use)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group (no abstinence from social media)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Treatment group (abstinence)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group (no abstinence)
Number of subjects: 415
Study: 27692491

Group type: EXPERIMENTAL
Intervention: TD-intervention targeted patient-only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TS-intervention targeted patients and family members
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control - a handout on staying healthy during treatment
Number of subjects: 0
Study: 26406079

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation system using serious games
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (neurotypical development)
Number of subjects: 20
Study: 23596089

Group type: EXPERIMENTAL
Intervention: 50% discount on low-energy density fruits and vegetables (F&V), bottled water, and diet sodas
Number of subjects: 47
Study: 21304815

Group type: EXPERIMENTAL
Intervention: High-protein meal (En% P/C/F 65/5/30)
Number of subjects: 38

Group type: COMPARATOR
Intervention: High-carbohydrate meal (En% P/C/F 6/64/30)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 38

Group type: COMPARATOR
Intervention: High-protein vs. high-carbohydrate meal
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Men vs. Women
Number of subjects: 38
Study: 19286349

Group type: EXPERIMENTAL
Intervention: Nutritional intervention for patients with SMI taking olanzapine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nutritional intervention for healthy controls
Number of subjects: 82
Study: 18181382

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 200 mg
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 300 mg
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 16765499

Group type: EXPERIMENTAL
Intervention: Intervention group (filled out the questionnaire four times during 6 months and received routine clinical care)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (received routine clinical care only)
Number of subjects: 210
Study: 16281465

Group type: EXPERIMENTAL
Intervention: Prophylactic laser treatment to the retina
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1052
Study: 10917540

Group type: EXPERIMENTAL
Intervention: Protracted venous infusional 5-fluorouracil (PVI 5-FU) alone or PVI 5-FU and mitomycin C (MMC)
Number of subjects: 11
Study: 8756915

Group type: EXPERIMENTAL
Intervention: Digital chest images obtained with a selenium detector
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional radiographs
Number of subjects: 104
Study: 1382217

Group type: EXPERIMENTAL
Intervention: Traffic wardens (exposed group)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Hospital staff members (control group)
Number of subjects: 292
Study: 3003305

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxprenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study: 31607823

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) sessions offered weekly (VRidays) and access to high-end VR stations in the Nexus Reality Lab.
Number of subjects: 0
Study: 27848017

Group type: EXPERIMENTAL
Intervention: Short-interval, low-intensity, slow-jogging (SJ) program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 26009595

Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 800

Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 800
Study: 23604335

Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 64
Study: 21572163

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 421

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 421
Study: 17629752

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC) followed by cyclophosphamide, methotrexate, fluorouracil (CMF)
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin and white blood cells (WBC)
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Age, surgery type, platelets, body mass index, and length of time from surgery to chemotherapy
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 2215
Study: 17371885

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with tapered high-dose prednisone (group 3)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab (group 4)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Sequential monotherapy (group 1)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Step-up combination therapy (group 2)
Number of subjects: 508
Study: 15125017

Group type: EXPERIMENTAL
Intervention: Manuka honey (UMF 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sugarless chewing gum (control)
Number of subjects: 30
Study: 11351935

Group type: EXPERIMENTAL
Intervention: 12 hours of smoking deprivation (tobacco-deprived smokers)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nondeprived smokers
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Smokers (both deprived and nondeprived)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Smoking deprivation
Number of subjects: 55
Study: 9141930

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 41
Study: 8201375

Group type: EXPERIMENTAL
Intervention: CYVADIC chemotherapy (cyclophosphamide 500 mg/m2 IV bolus on day 1, vincristine 1.4 mg/m2 IV bolus on day 1, doxorubicin 50 mg/m2 IV bolus on day 1, dacarbazine 400 mg/m2 by 1-hour infusion on days 1 to 3, repeated every 28 days for eight courses)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: CYVADIC chemotherapy
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 317
Study: 3662061

Group type: EXPERIMENTAL
Intervention: midazolam 0.2 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: thiopental 3.5 mg/kg
Number of subjects: 60
Study: 31972745

Group type: EXPERIMENTAL
Intervention: Blocking group (screw heads blocking superior-adjacent bilateral facets)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (intact noninstrumented spine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison between blocking and control groups
Number of subjects: 12
Study: 29549523

Group type: EXPERIMENTAL
Intervention: High cadence (90 r/min) + taurine (50 mg/kg body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: High cadence (90 r/min) + placebo (3 mg/kg body mass maltodextrin)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low cadence (50 r/min) + taurine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low cadence (50 r/min) + placebo
Number of subjects: 9
Study: 28207287

Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25867422

Group type: EXPERIMENTAL
Intervention: External rhGM‐CSF gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhGM‐CSF gel matrix components (Control)
Number of subjects: 0
Study: 24268210

Group type: EXPERIMENTAL
Intervention: Cardiovascular Magnetic Resonance (CMR)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Routine clinical management
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: CMR or CTA
Number of subjects: 321
Study: 21036772

Group type: EXPERIMENTAL
Intervention: Once-daily regimen of emtricitabine, didanosine and efavirenz
Number of subjects: 355

Group type: COMPARATOR
Intervention: Protease inhibitor‐based regimen
Number of subjects: 355
Study: 18855829

Group type: EXPERIMENTAL
Intervention: CBT + voicemail monitoring and telephone counseling
Number of subjects: 304

Group type: COMPARATOR
Intervention: Telephone-based general support
Number of subjects: 304
Study: 16553634

Group type: EXPERIMENTAL
Intervention: Adjunctive metronidazole plus amoxicillin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adjunctive metronidazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 43

Group type: COMPARATOR
Intervention: Scaling and root planning (SRP)
Number of subjects: 43
Study: 15292323

Group type: EXPERIMENTAL
Intervention: Continuation of GH therapy (0.35 U/kg.wk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cessation of GH therapy
Number of subjects: 24
Study: 10863716

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 10
Study: 8874913

Group type: EXPERIMENTAL
Intervention: Midazolam 15 micrograms.kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 30 micrograms.kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 45 micrograms.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Group PLAC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam groups (combined M-15, M-30, M-45)
Number of subjects: 90
Study: 1348442

Group type: EXPERIMENTAL
Intervention: High fear exposure
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low fear exposure
Number of subjects: 65

Group type: COMPARATOR
Intervention: Moderate fear exposure (control group)
Number of subjects: 65
Study: 3874643

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 over 5 s
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 over 20 s
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 over 60 s
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5-s group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20-s group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60-s group
Number of subjects: 60
Study: 31657982

Group type: EXPERIMENTAL
Intervention: DDIR signature positive
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: sTILs density ≥ 20%
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: DDIR positivity and T1c/T2N0 disease
Number of subjects: 425
Study: 30565735

Group type: EXPERIMENTAL
Intervention: LET's CONNECT (LC)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 218
Study: 27387658

Group type: EXPERIMENTAL
Intervention: Baseline LDCT screening
Number of subjects: 26004
Study: 24709712

Group type: EXPERIMENTAL
Intervention: 50mg tramadol (TRA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 100mg tramadol (TRA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both dosages (50mg and 100mg)
Number of subjects: 19
Study: 22416821

Group type: EXPERIMENTAL
Intervention: Middle albumin:creatinine ratio tertile (n=50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High albumin:creatinine ratio tertile (n=50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lower albumin:creatinine ratio tertile (n=50)
Number of subjects: 150
Study: 19487320

Group type: EXPERIMENTAL
Intervention: Gaboxadol (GBX) 5, 10, and 15 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Zolpidem (ZOL) 10 mg
Number of subjects: 81
Study: 18031818

Group type: EXPERIMENTAL
Intervention: 1CU accommodating IOL
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 90

Group type: COMPARATOR
Intervention: Monofocal IOL (control group)
Number of subjects: 90
Study: 16680965

Group type: EXPERIMENTAL
Intervention: MEBO treatment
Number of subjects: 598

Group type: COMPARATOR
Intervention: SD-Ag cream treatment
Number of subjects: 598
Study: 12934781

Group type: EXPERIMENTAL
Intervention: Vital sign stamp intervention
Number of subjects: 9439

Group type: COMPARATOR
Intervention: Control condition (no vital sign stamp)
Number of subjects: 9439
Study: 10986219

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA) 5 g intravenously
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9380238

Group type: EXPERIMENTAL
Intervention: Dialysis patients with elevated plasma silicon levels (3,849 and 2,350 micrograms/l)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dialysis patients (n=30)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Plasma Si levels
Number of subjects: 2